Literature DB >> 11423760

Hypocomplementemic type II membranoproliferative glomerulonephritis in a male patient with familial lecithin-cholesterol acyltransferase deficiency due to two different allelic mutations.

A Sessa1, G Battini, M Meroni, G Daidone, I Carnera, P L Brambilla, G Viganò, F Giordano, F Pallotti, L Torri Tarelli, L Calabresi, M Rolleri, S Bertolini.   

Abstract

Patients with familial lecithin-cholesterol acyltransferase (LCAT) deficiency very often show progressive glomerulosclerosis with evolution to end-stage disease. High levels of an abnormal lipoprotein (lipoprotein X) cause glomerular capillary endothelial damage. The ultrastructural study of renal biopsy specimens shows characteristic glomerular deposits of membrane-like, cross-striated structures and vacuole structures. The gene encoding for LCAT has been mapped to chromosome 16q22.1, and several mutations of this gene cause LCAT deficiency which is inherited as an autosomal recessive trait and which is characterized by corneal opacities, normochromic normocytic anemia, and renal dysfunction. Herein we report clinical features and renal histological findings concerning a 24-year-old male patient with classical familial LCAT deficiency due to two different allelic mutations: a nonsense mutation inherited from the father and a missense mutation inherited from the mother. Moreover, the patient showed glomerular histological lesions and an immunofluorescent glomerular pattern typical of hypocomplementemic membranoproliferative type II glomerulonephritis (dense-deposit disease). The nature of electron-dense material that characterizes dense-deposit disease is still unknown, but there are suggestions that some chemical modifications might occur in the renal basement membranes. Therefore, this clinical case might induce to consider possible relations between disorders of the lipoprotein metabolism and renal dense-deposit disease. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11423760     DOI: 10.1159/000046001

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  6 in total

1.  Corticosteroid treatment of kidney disease in a patient with familial lecithin-cholesterol acyltransferase deficiency.

Authors:  Przemysław Miarka; Barbara Idzior-Waluś; Marek Kuźniewski; Małgorzata Waluś-Miarka; Tomasz Klupa; Władysław Sułowicz
Journal:  Clin Exp Nephrol       Date:  2011-02-16       Impact factor: 2.801

2.  Progression of chronic kidney disease in familial LCAT deficiency: a follow-up of the Italian cohort.

Authors:  Chiara Pavanello; Alice Ossoli; Marcello Arca; Laura D'Erasmo; Giuliano Boscutti; Loreto Gesualdo; Tiziano Lucchi; Tiziana Sampietro; Fabrizio Veglia; Laura Calabresi
Journal:  J Lipid Res       Date:  2020-09-30       Impact factor: 5.922

3.  Lipoprotein X Causes Renal Disease in LCAT Deficiency.

Authors:  Alice Ossoli; Edward B Neufeld; Seth G Thacker; Boris Vaisman; Milton Pryor; Lita A Freeman; Christine A Brantner; Irina Baranova; Nicolás O Francone; Stephen J Demosky; Cecilia Vitali; Monica Locatelli; Mauro Abbate; Carlamaria Zoja; Guido Franceschini; Laura Calabresi; Alan T Remaley
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

Review 4.  High-Density Lipoproteins and the Kidney.

Authors:  Arianna Strazzella; Alice Ossoli; Laura Calabresi
Journal:  Cells       Date:  2021-03-31       Impact factor: 6.600

Review 5.  A systematic review of the natural history and biomarkers of primary lecithin:cholesterol acyltransferase deficiency.

Authors:  Cecilia Vitali; Archna Bajaj; Christina Nguyen; Jill Schnall; Jinbo Chen; Kostas Stylianou; Daniel J Rader; Marina Cuchel
Journal:  J Lipid Res       Date:  2022-01-20       Impact factor: 5.922

6.  LCAT deficiency: a systematic review with the clinical and genetic description of Mexican kindred.

Authors:  Roopa Mehta; Daniel Elías-López; Alexandro J Martagón; Oscar A Pérez-Méndez; Maria Luisa Ordóñez Sánchez; Yayoi Segura; Maria Teresa Tusié; Carlos A Aguilar-Salinas
Journal:  Lipids Health Dis       Date:  2021-07-13       Impact factor: 3.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.